Also found in: Wikipedia.

difluprednate (ophthalmic)

(dye-floo-pred-nate) ,


(trade name)


Therapeutic: ocular agents
Pharmacologic: corticosteroids
Pregnancy Category: C


Treatment of inflammation and pain associated with ocular surgery.


Decreases inflammation.

Therapeutic effects

Decreased pain and inflammation following ocular surgery.


Absorption: Limited systemic absorption.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile



Contraindicated in: Active viral, mycobacterial or fungal infection of eyes and surrounding structures.
Use Cautiously in: Obstetric: Use in pregnancy only if potential benefit justifies potential risk to the fetus; Lactation: Use cautiously during lactation; Pediatric: Safety and effectiveness in children have not been established.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • ↑ intraocular pressure
  • blepharitis
  • cataracts
  • conjunctival hyperemia
  • corneal edema
  • delayed healing
  • eye pain
  • infections
  • iritis
  • photophobia


Drug-Drug interaction

None noted.


Ophthalmic (Adults) 1 drop four times daily, starting 24 hr after surgery for 2 wk, then twice daily for one week, then further tapered based on response.


Ophthamic emulsion: 0.05% in 5 mL bottle

Nursing implications

Nursing assessment

  • Assess affected eye for pain and swelling during therapy.
  • Monitor intraocular pressure of difluprednate is used more than 10 days.

Potential Nursing Diagnoses

Acute pain (Indications)


  • Ophthalmic: Instill 1 drop into conjunctival sac of affected eye 4 times/day beginning 24 hrs after surgery and continuing throughout first 2 wks of postoperative period, followed by twice daily for a wk, then base dose on patient response.

Patient/Family Teaching

  • Instruct patient in correct technique and frequency for instillation of eye drops (see ).
  • Instruct patient to avoid wearing contact lenses during therapy.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
  • Advise patient to notify health care professional if redness, itching or inflammation develops or becomes aggravated.

Evaluation/Desired Outcomes

  • Decrease in eye pain and inflammation following ocular surgery.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Prednisolone acetate 1% or equivalent, or difluprednate 0.05% without BAK, was prescribed QID, 1-4 weeks postsurgery, TID, week 5 postoperative, BID, week 6 postoperative, and QD, 7-12 weeks postsurgery.
Postoperatively, topical moxifloxacin was given for 2 weeks and difluprednate for 6 weeks on a slow taper.
There are no human eye data for five topical corticosteroids: difluprednate (Durezol), fluorometholone (Flarex, Fluor-OP, FML), loteprednol (Alrex, Lotemax), prednisolone (Econopred), and rimexolone (Vexol).
Fluromethalone (92; 60.53%) was the most commonly prescribed steroid followed by loteprednol (40; 26.32%), and difluprednate (20; 13.16%).
along with difluprednate 0.05% (Durezol) every hour and loteprednol etabonate 0.5% (Lotemax) ointment at night in each eye.
Difluprednate ophthalmic emulsion 0.05%, a strong topical steroid, was approved by US Food and Drug Administration (FDA) in June 2008, for treatment of ocular inflammation and pain associated with ocular surgery [5,6] along with less frequency of dosage (4 times) for better patient compliance.
In June 2008 difluprednate ophthalmic emulsion 0.05% was approved by the US Food and Drug Administration (FDA) for the treatment of inflammation and pain associated with ocular surgery.
Earlier prednisolone acetate 1% suspension was gold standard for post cataract surgery patients but now difluprednate, a new potent steroid is available in market with broad spectrum anti-inflammatory activity.